ImageneBio Inc (IMA) Stock Analysis

What ImageneBio Inc does

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Key metrics

ETFs linked to IMA

Broad-market and Healthcare sector ETFs an investor holding ImageneBio Inc is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how IMA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for ImageneBio Inc?

ImageneBio Inc trades under the ticker IMA on NASDAQ.

Which exchange is IMA listed on?

IMA is listed on NASDAQ.

What sector does ImageneBio Inc operate in?

ImageneBio Inc is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze IMA in a portfolio?

PortView shows IMA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.